Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VFX
|
|||
| Former ID |
DIB003957
|
|||
| Drug Name |
SAR342434
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Phase 3 | [1] | |
| Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 3 | [2], [3] | ||
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [2] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02273180) Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.